- International classification of retinopathy of prematurity, third edition.Ophthalmology. 2021; 128: e51-e68
- Fulminate retinopathy of prematurity - clinical characteristics and laser outcome.Indian J Ophthalmol. 2005; 53: 261-265
- A hybrid form of retinopathy of prematurity.Br J Ophthalmol. 2012; 96: 519-522
Publication stageIn Press Journal Pre-Proof
Disclosure(s): All authors have completed and submitted the ICMJE disclosures form.
The authors made the following disclosures: M. F. C.: Consultant – Novartis; Equity owner – InTeleretina; Research support – Genentech, National Institutes of Health, National Science Foundation.
A.R.F.: Consultant – Novartis, Bayer.
R.V.P.C.: Scientific Advisory Board – Phoenix Technology; Consultant – Alcon, Novartis.
J.P.C.: Research funding – National Institutes of Health (grant no. R01EY19474 , K12EY27720 ), National Science Foundation (grant no. SCH-1622679), Genentech.
A.C.: Equity owner – Phoenix Technology Group, LLC; Founder and equity owner – Retinal Solutions, LLC; Research support – AURA Biosciences, Bayer, Genentech, Ionis Pharmaceuticals, Novartis, Regeneron Pharmaceuticals.
B.F.: Consultant – Novartis.
M.E.H.: Research support – National Institutes of Health (grant nos. R01EY017011, F01EY01730, EY014800); Consultant – Regeneron.
D.L.: Consultant – Novartis, Bayer.
Ş.Ö.: Consultant – Novartis, Bayer, Allergan.
A.S.: Research support – Novartis; Consultant – Novartis, Bayer.
C.T.: Research support – National Institutes of Health (grant nos. R01EY025009, U01EY028079, P30EY005722), Research to Prevent Blindness Stein Award; Royalties – Alcon; Founding and equity owner – Theia Imaging, LLC.
W.-C.W.: Consultant – Novartis, Bayer, Allergan.
Supported by a grant from the Knights Templar Eye Foundation; by departmental funding from the Illinois Eye and Ear Infirmary at the University of Illinois at Chicago (Chicago, IL); and by grants R01EY19474, K12EY027720, P30EY001792, and P30EY10572 from the NIH (Bethesda, MD). The sponsor or funding organization had no role in the design or conduct of this research.